Literature DB >> 6788763

Release and metabolism of arachidonic acid in human neutrophils.

C E Walsh, B M Waite, M J Thomas, L R DeChatelet.   

Abstract

Dual radiolabel incorporation of [3H]arachidonic acid and [14C]palmitate or [14C]stearate by human neutrophils was employed to study both the release and metabolism of arachidonic acid. Results indicate the involvement of a phospholipase A2 mechanism causing [3H]arachidonate release from membrane phospholipid. Phosphatidylinositol and phosphatidylcholine were the sources of [3H]arachidonate; about twice as much radiolabeled phosphatidylinositol was degraded as phosphatidylcholine. Challenge of neutrophils with opsonized zymosan and calcium ionophores caused the release of [3H]arachidonate; however, ionophores but not opsonized zymosan led to the production of [3H]hydroxyicosatetraenoic acid and [3H]dihydroxyicosatetraenoic acid. These products were preferentially released by neutrophils into the extracellular milieu in contrast with free [3H]arachidonate which remained cell associated. One-third of the [3H]hydroxyicosatetraenoic acid but not [3H]dihydroxyicosatetraenoic acid was reincorporated into cellular lipid, primarily phospholipid. No significant production of [3H]prostaglandin or [3H]thromboxane was detected. In contrast to zymosan and ionophore, phorbol myristate acetate, another potent stimulant of neutrophil oxidative metabolism and degranulation, did not release [3H]arachidonate.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6788763

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Investigation of the dependence of human middle cerebral artery contractile activity on the presence of an atherosclerotic patch.

Authors:  S E Akopov; M R Grygorian; E S Gabrielian; B H Balayan
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

2.  The endothelium-dependent relaxation of human middle cerebral artery: effects of activated neutrophils.

Authors:  S E Akopov; M R Grigorian; E S Gabrielian
Journal:  Experientia       Date:  1992-01-15

Review 3.  Molecular mechanisms of calcium-induced membrane fusion.

Authors:  D Papahadjopoulos; S Nir; N Düzgünes
Journal:  J Bioenerg Biomembr       Date:  1990-04       Impact factor: 2.945

4.  Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action.

Authors:  H Makino; T Saijo; Y Maki
Journal:  Agents Actions       Date:  1989-11

5.  Regulation of phosphatidylinositol turnover, calcium metabolism and enzyme secretion by phorbol dibutyrate in neutrophils.

Authors:  C M Kramer; R C Franson; R P Rubin
Journal:  Lipids       Date:  1984-05       Impact factor: 1.880

6.  Receptor-mediated activation of a phospholipase A2 in rabbit neutrophil plasma membrane.

Authors:  B J Bormann; C K Huang; W M Mackin; E L Becker
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

7.  Incorporation of fatty acids into phospholipids in L cells stimulated by antibody.

Authors:  W T Shearer; R G Ulrich
Journal:  Lipids       Date:  1984-04       Impact factor: 1.880

8.  Role of arachidonic acid and its metabolites in the priming of NADPH oxidase in human polymorphonuclear leukocytes by peritoneal dialysis effluent.

Authors:  I Daniels; M A Lindsay; C I Keany; R P Burden; J Fletcher; A P Haynes
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

9.  Role of hydrogen peroxide in the neutrophil-mediated release of prostacyclin from cultured endothelial cells.

Authors:  J M Harlan; K S Callahan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

10.  Arachidonic acid metabolism in normal and hypereosinophilic syndrome human eosinophils: generation of leukotrienes B4, C4, D4 and 15-lipoxygenase products.

Authors:  W R Henderson; J B Harley; A S Fauci
Journal:  Immunology       Date:  1984-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.